Evidence map›Paper›PMID 37602701›Full record

ArticleThe Journal of clinical endocrinology and metabolism2024

Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.

Juan Pablo Frías, Rodolfo J Galindo, Hui Wang, Raleigh E Malik, K Karthik Chivukula, Juan M Maldonado

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Juan Pablo FríasVelocity Clinical Research, Los Angeles, CA 90057, USA.
Rodolfo J GalindoDivision of Endocrinology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Hui WangTechData Service, King of Prussia, PA 19406, USA.
Raleigh E MalikLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
K Karthik ChivukulaLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Juan M MaldonadoLilly Research Laboratories, Eli Lilly and Company, San Juan 00918, Puerto Rico.ORCID 0000-0002-1370-327X
Eli Lilly (United States) · USUniversity of Miami · USVelocity Clinical Research (United States) · US

Funding

Technologies Advancing Translation - Regional CoreP30DK111024 · EMORY UNIVERSITY · 2025 to 2025
$775k
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Rodolfo Galindo · 2022 to 2024
$369k
Eli Lilly and CompanyNIDDK NIH HHS K23 DK123384NIDDK NIH HHS P30 DK111024
6 · The paper itself

Abstract

contextEfficacy and safety of tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, have been studied in patients with type 2 diabetes in the global phase 3 SURPASS program.

objectiveThis work aimed to assess the efficacy and safety of tirzepatide in Hispanic/Latino and non-Hispanic/Latino patients in SURPASS-1 to -4 clinical trials.

methodsA total of 5679 patients were included, 2895 of self-reported Hispanic/Latino ethnicity, in this exploratory analysis of SURPASS-1 to -4 trial data. Interventions included tirzepatide 5, 10, or 15 mg, placebo, or active comparator (semaglutide 1 mg, insulin degludec, and insulin glargine). Change in glycated hemoglobin A1c (HbA1c) and body weight from baseline to week 40 (SURPASS-1 and -2) and to week 52 (SURPASS-3 and -4), and other efficacy and safety outcomes were evaluated within Hispanic/Latino and non-Hispanic/Latino subgroups.

resultsAmong Hispanic/Latino and non-Hispanic/Latino patients treated with tirzepatide, respectively, HbA1c decreased significantly from baseline, ranging from 1.9% to 2.7% and 1.7% to 2.5%, and body weight decreased significantly from baseline, ranging from 5.3 kg to 12.4 and 6.5 kg to 17.1 kg (both P < .05) vs comparators across all trials. Subgroup trends were consistent with the overall trial populations. Treatment-emergent adverse events were reported in similar proportions across the subgroups and were primarily gastrointestinal disorders. The incidence of hypoglycemia was low.

conclusionTirzepatide significatively reduced HbA1c and body weight in Hispanic/Latino and non-Hispanic/Latino patients. Tirzepatide was generally well tolerated in both subgroups. Efficacy and safety trends were comparable between subgroups and within the overall trial populations.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsBody WeightGastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorGlycated HemoglobinHispanic or LatinoHumansTirzepatideGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-2 ReceptorGlycated HemoglobinHypoglycemic AgentsIncretinsTirzepatideGIP and GLP-1 receptor agonistglycemic controlHispanic/Latinoincretin therapytirzepatidetype 2 diabetes

Identifiers

PMID37602701
PMCPMC10795909
OpenAlexW4386019837

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.